Emyria

D4, 661 Newcastle Street
Leederville WA 6007

Home

Contact Us

Updates

Corporate Governance

Annual Reports

Share Price

Announcements

New investors

Why Invest in Emyria?

Investor Research

Loyalty Option Offer

Presentations

Successes

Meet the Team

About Emyria

Webinars

Montserrat

Emyria Limited

upload.jpg

Emyria (ASX:EMD) has today announced a multi-year agreement with Medibank - Australia’s leading health insurer supporting over 4.2 million customers - to fund eligible participation in our Treatment-Resistant Depression (TRD) program at Perth Clinic.

Depression affects 4.6% of the Australian population each year, and for one-third of these individuals, symptoms persist despite standard care. Treatment resistance represents a major unmet need, driving significant personal, social, and economic burden, making access to new, evidence-based care models critically important.

This partnership builds on Medibank’s earlier support for Emyria’s PTSD program and introduces improved access to care for TRD, removing financial barriers for those most in need.

Emyria Executive Chair, Greg Hutchinson, said:

“This landmark agreement with Medibank means eligible patients with treatment-resistant depression can now access world-class care without financial burden, and together with our PTSD program, Emyria has established two insurer-funded treatment pathways for Australians facing some of the most challenging mental health conditions. The strong demand at Perth Clinic and the progress of our Brisbane expansion confirm the scalability of our Empax Model, and we are proud to partner with Medibank and leading hospitals to build a sustainable, data-driven mental health platform that can grow nationally and deliver lasting impact for patients and the healthcare system.”

Medibank to Fund Emyria’s Depression Treatment at Perth Clinic